Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 in Early Rheumatoid Arthritis
NCT04004429Phase 2Completed
- Sponsor
- SynAct Pharma AB
- Start
- Aug 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of resomelagon in rheumatoid arthritis (RA), sponsored by SynAct Pharma AB. Started Aug 2019; status: completed.
02
Drugs
resomelagon
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04004429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004429.